Related Experiment Video
Updated: Jan 16, 2026
Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models
Published on: January 14, 2020
Functional Precision in Pancreatic Cancer: Redefining Biomarkers with Patient-Derived Organoids
Claire Alexandra Chew1,2, Cheng Mun Wun1,2, Yi Fang Lee1,2
1Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.
Abstract:
Pancreatic cancer remains a lethal disease despite advances in surgery and systemic treatment in the last two decades, underscoring the urgent need to better understand its biological underpinnings. Despite remarkable advances in the molecular characterization of pancreatic ductal adenocarcinoma (PDAC), clinically actionable biomarkers remain scarce, and current treatment remains empiric. Transcriptomic subtypes such as "classical" and "basal-like" offer some prognostic value, but their ability to guide real-time treatment decisions is limited. In this review, we explore the limitations of current biomarker strategies, in particular subtype-based classifications, and argue for a functional reframing of biomarker development in PDAC, centered on patient-derived organoids (PDOs). We explore four key domains in which PDOs deepen our understanding of therapeutic response and resistance, namely, drug response phenotyping, modeling chemoresistance, incorporating tumor microenvironmental complexity through co-culture systems, and more functional profiling through proteomic and metabolomic approaches. Together, these applications move PDOs beyond static avatars of the tumor to dynamic platforms capable of capturing clinically relevant biology. As functional precision medicine gains traction, PDOs may offer a path to more tailored, responsive treatment strategies in a cancer where new options are urgently needed.
Insights
Pancreatic cancer research needs better biomarkers. Patient-derived organoids (PDOs) offer a dynamic platform for functional precision medicine, improving therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Biomarker Discovery
- Translational Medicine
Background:
- Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), has a poor prognosis despite treatment advances.
- Current molecular subtypes lack clinical utility for real-time treatment decisions.
- Clinically actionable biomarkers for PDAC are urgently needed.
Purpose of the Study:
- To review limitations of current PDAC biomarker strategies.
- To propose a functional reframing of biomarker development using patient-derived organoids (PDOs).
- To highlight PDOs' potential in advancing precision medicine for PDAC.
Main Methods:
- Review of current literature on PDAC biomarkers and patient-derived organoids.
- Exploration of four key domains of PDO application: drug response phenotyping, modeling chemoresistance, incorporating tumor microenvironment, and functional profiling (proteomics, metabolomics).
Main Results:
- Current subtype classifications offer limited prognostic value and do not guide treatment effectively.
- Patient-derived organoids (PDOs) serve as dynamic platforms for capturing clinically relevant biology.
- PDOs enable functional profiling, including drug response, chemoresistance, and tumor microenvironment interactions.
Conclusions:
- Patient-derived organoids (PDOs) represent a promising functional approach to biomarker development in PDAC.
- PDOs facilitate a shift from static tumor avatars to dynamic platforms for personalized medicine.
- Functional precision medicine using PDOs may lead to more tailored and effective treatment strategies for pancreatic cancer.
More Related Videos
07:31Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
Published on: May 26, 2023
09:19Organotypic Slice Cultures as Preclinical Models of Tumor Microenvironment in Primary Pancreatic Cancer and Metastasis
Published on: June 22, 2021